27/07/2021 2:30 pm Welcome to isteroids.com - BLOG

Wednesday 21, Apr 2010

  Skin rash signifies improved outcomes for lung and pancreatic cancer patients

Posted By
Pin it Share on Tumblr

Skin rash signifies improved outcomes for lung and pancreatic cancer patientsThe appearance of a rash in patients suffering from cancer and treated with erlotinib (Tarceva) is strongly associated with longer survival, as per researchers from the drug’s developer, OSI Pharmaceuticals, Inc.

This is not the first time that rashes have been linked with a survival advantage in regard to a class of drugs, EGFR (epidermal growth factor receptor) inhibitors, which include erlotinib, cetuximab, panitumumab and others designed for blocking overproduction of EGFR but this was hailed as the most detailed analysis to date.

The study was published in the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research.

Monday 19, Apr 2010

  Preemptive treatment helps in preventing skin toxicity with Panitumumab

Posted By
Pin it Share on Tumblr

Preemptive treatment helps in preventing skin toxicity with PanitumumabPatients receiving panitumumab for treating metastatic colorectal cancer can avoid some of the skin-associated toxicities with a preemptive and prophylactic skin regimen, as per data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented data from the study that was the first prospective study for comparing preemptive and reactive skin treatment for skin toxicities related to panitumumab.

The study was co-led by Dr. Mitchell and Mario Lacouture, M.D., an assistant professor of Dermatology at Northwestern University‘s Feinberg School of Medicine in Chicago.

Tuesday 16, Mar 2010

  Preemptive treatment with Panitumumab helps in curbing skin toxicity

Posted By
Pin it Share on Tumblr

Preemptive treatment with Panitumumab helps in curbing skin toxicitySome of the skin-associated toxicities that occur in patients receiving panitumumab for treatment of metastatic colorectal cancer may be avoided with a preemptive, prophylactic skin regimen.

This finding was disclosed in data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented data from the study, which was co-led by Dr. Mitchell and Mario Lacouture, M.D., an assistant professor of Dermatology at Northwestern University’s Feinberg School of Medicine in Chicago.

Thursday 24, Dec 2009

  Pre-emptive treatment with Panitumumab effective for curtailing skin toxicity

Posted By
Pin it Share on Tumblr

Pre-emptive treatment with Panitumumab effective for curtailing skin toxicityAccording to data presented at the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco, skin-associated toxicities can be avoided to a significant extent with a pre-emptive and prophylactic skin regimen in patients receiving panitumumab for treatment of metastatic colorectal cancer.

Edith Mitchell, M.D., a clinical professor in the Department of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, presented study data. This study was co-led by Dr. Mitchell and Mario Lacouture, M.D., an assistant professor of Dermatology at Northwestern University’s Feinberg School of Medicine in Chicago.

It was remarked by Dr. Lacouture that the study supports the notion that it is better to treat prophylactically, than to wait for the side effect to fully develop.